Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $33

Benzinga Newsdesk www.benzinga.com Negative 84.7%

Neg 84.7% Neu 0% Pos 0%

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $103 to $33.